WO2005082390A1 - 脂肪蓄積抑制剤 - Google Patents
脂肪蓄積抑制剤 Download PDFInfo
- Publication number
- WO2005082390A1 WO2005082390A1 PCT/JP2005/003178 JP2005003178W WO2005082390A1 WO 2005082390 A1 WO2005082390 A1 WO 2005082390A1 JP 2005003178 W JP2005003178 W JP 2005003178W WO 2005082390 A1 WO2005082390 A1 WO 2005082390A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fat accumulation
- fat
- accumulation inhibitor
- inhibitor according
- polyphenol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
Definitions
- the present invention relates to a fat accumulation inhibitor containing, as an active ingredient, a plant, preferably a Rosaceae plant, particularly a fruit polyphenol derived from apple fruit or immature fruit, and more particularly, polyphenol is a proanthocyanin, particularly A procyadine, a fat accumulation inhibitor having the effects of suppressing in-situulin elevation in the living body, suppressing lebutin elevation, and inhibiting fat accumulation per body weight, and foods, beverages, food additives, pharmaceuticals, and pharmaceuticals containing the same. Regarding quasi-drugs and feed. Background art
- obesity and increased body fat are considered to be risk factors for ischemic heart disease, stroke, diabetes, etc. soon after complicating hypertension and hyperlipidemia. It is.
- Patent Document 2 reports on inhibition of in vivo lipid oxidization, improvement of HDL (good cholesterol) Z total cholesterol ratio, and suppression of cholesterol absorption; fruit polyphenol procyanidin and fat accumulation With regard to the relationship, it is completely mentioned, what ,.
- Patent Document 3 Japanese Patent Application Laid-Open No. 7-285876
- Patent Document 2 Japanese Patent Application Laid-Open No. H10-330278
- Patent Document 3 JP-A-9-291039
- a fat accumulation inhibitor having the effect of suppressing the rise of insulin in the living body and the rise of lebutin, especially the effect of suppressing the accumulation of fat per body weight, without affecting the weight gain, increases the body fat percentage. It is expected to prevent and prevent hypertension, hyperlipidemia, ischemic heart disease, stroke, diabetes and the like!
- an object of the present invention is to provide a fat accumulation inhibitor that satisfies these properties and is derived from natural products and has no harmful effect on the human body.
- the present inventors have conducted intensive studies to find a natural product that has a fat accumulation inhibitory action and is safe in a high-fat diet system. As a result, polyphenol phenols derived from apple fruits or immature fruits were obtained. The present inventors have found that they have an inhibitory action on insulin rise in the body and an inhibitory action on lebutin increase, and in particular, have an inhibitory action on fat accumulation per body weight, and have reached the present invention. That is, according to the present invention, there is provided a fat accumulation inhibitor characterized by containing a polyphenol derived from fruit or immature fruit as an active ingredient.
- the fat accumulation inhibitor of the present invention suppresses an increase in insulin in vivo and an increase in lebutin. It suppresses fat accumulation per body weight by suppression or the like.
- the fat accumulation inhibitor of the present invention it is preferable to use a polyphenol derived from a rose plant, especially an apple fruit or an unripe fruit among plants.
- the fat accumulation inhibitor of the present invention can be used by being contained in foods, beverages, food additives, pharmaceuticals, quasi-drugs, and feeds.
- a fat characterized by containing, as an active ingredient, an apple extract or polyphenol or procyadine as an active ingredient, which is also extracted and purified from solanaceous plants, particularly apple fruit or immature fruit.
- An accumulation inhibitor is provided, and the function of the fat accumulation inhibitor to suppress visceral fat accumulation, hyperinsulinemia, hyperlebutinemia, and the like can suppress fat accumulation.
- the fat accumulation inhibitor of the present invention can be used for foods and beverages, food additives, pharmaceuticals, quasi-drugs for those who are concerned about increased body fat, obesity, hyperlipidemia, arteriosclerosis, diabetes, etc. And animal feed.
- FIG. 1 is a graph showing the effect of suppressing the mesenteric fat accumulation by an animal experiment using apple polyphenol.
- FIG. 2 is a graph showing the effect of suppressing the total visceral fat accumulation by an animal experiment using apple polyphenol.
- FIG. 3 is a graph showing the inhibitory effect of apple polyphenol on an increase in blood insulin concentration in animal experiments.
- FIG. 4 is a graph showing the effect of suppressing the increase in blood lebutin concentration in animal experiments using apple polyphenol.
- the polyphenol used in the present invention is a fruit or immature fruit extract that is a purified polyphenol fraction.
- the polyphenol fraction is firstly a juice of raw material fruit or water or ethanol.
- An extract obtained by using the above organic solvent can be used.
- the juice from which the squeezed juice or the organic solvent has been removed can be used as it is, but through steps such as centrifugation and filtration, a clear juice or extract can be obtained, and the polyphenol fraction can be obtained.
- the polyphenol fraction can then be concentrated to obtain a liquid preparation, and further, the concentrate can be spray-dried or freeze-dried to obtain a powder preparation.
- a fruit preferably a fruit of a Rosaceae plant, specifically, an apple, a pear, a peach, a rice cake, or the like can be used as a raw material. .
- immature fruits are particularly preferable because they contain more polyphenols than can be used for both mature fruits and immature fruits, and contain many active ingredients having a wide range of physiological functions.
- the dose of the fat accumulation inhibitor described in the present invention, and the insulin elevation inhibitor and the lebutin elevation inhibitor used as an oral agent vary depending on the purpose of administration and the gender, age, weight, and health status of the administration subject. Force can be administered in the range of lmg Zkg body weight to lOOmg Zkg body weight as the weight of the dry polyphenol fraction.
- the apple-derived polyphenol of the present invention is a fruit used as a raw material in food, so there is no problem in terms of safety.However, the acute toxicity test, the chronic toxicity test, and the mutation Various safety tests such as a safety test are conducted to confirm the safety.
- the polyphenol fraction obtained as described above includes flavonols such as caffeic acid derivatives (esters) such as chlorogenic acid, P-tamaric acid derivatives, flavan 3-ols (catechins) and quercetin glycoside, and phloretin. It is composed of chalcones such as glycosides and polyphenols such as procyadins such as procyadine B-2. Inhibition of elevation, suppression of mutagenicity, allergy It has already been confirmed that it has physiological functions such as unisex suppression, pile caries, deodorization, and control of lipid metabolism in vivo (JP-A-7-285876, JP-A-10-330278).
- flavonols such as caffeic acid derivatives (esters) such as chlorogenic acid, P-tamaric acid derivatives, flavan 3-ols (catechins) and quercetin glycoside, and phloretin. It is composed of chalcones such as glycosides and polyphenol
- polyphenol had a function of suppressing the accumulation of visceral fat. That is, polyphenols containing the above-mentioned procyazines as main components are extremely effective in suppressing body fat accumulation.
- the polyphenol had a function of suppressing an increase in insulin. That is, the polyphenols containing the above-described procyazines as main components are extremely effective in improving hyperinsulinemia.
- polyphenol had a function of suppressing the rise of lebutin. That is, polyphenols containing the above-described procyazines as main components are extremely effective in improving hyperleptinemia.
- Adipose tissue weight After breeding, peri-kidney (retroperitoneal), peri-testis (epitestis) and mesenteric adipose tissues were collected and weighed.
- Serum insulin and leptin levels were measured as indicators related to obesity using a commercially available ELISA kit (insulin: ELISA kit from Mercodia; leptin: Yanaihara Institute ELISA kit).
- the fat accumulation rate was suppressed, and the change in body fat percentage (total Visceral fat increase ⁇ weight gain x 100)
- the fat diet group (7.36-4.94) ⁇ 424.7 X 100 0.56%
- X 100 0.24%
- the resulting fractional alcohol was concentrated under reduced pressure to prepare about 2 kg of an extracted powder product.
- chlorogenic acids about 20%
- phlorethylene glycosides about 5%
- flavonols about 15%
- proanthocyanin about 50%
- other browning substances about 10%
- this protociadinin liability is composed of a matrix-assisted laser ionization-time-of-flight mass spectrometer (MALDI-TOFZMS, manufactured by Applied Biosystems Inc.). Oligomers and polymers ranging from dimers to 15-mers were confirmed. (M. Ohnishi-kameyama et al. Mass spectrometry, 11, 31-36, 1997)
- This test meal was prepared by mixing a tablet containing apple polyphenol (150 mg Zl tablet) manufactured in a practical example and a polyphenol manufactured in a comparative example, and was used as a control food (placebo tablet). Before the test, the investigator confirmed that the test drink and the placebo tablet were indistinguishable due to the sensory surface such as flavor and aroma, and the package. Ingestion method and schedule
- the study was a parallel two-group comparative study employing a double-blind method by random assignment.
- the study period was set for a total of 20 weeks: 4 weeks of early observation, 12 weeks of ingestion, and 4 weeks of observation after ingestion.
- the subjects were divided into two groups and consumed test tablets in the following manner.
- Group A 4 tablets each of apple polyphenol-containing test tablets (150 mg Zl tablets) before dinner (total 4 tablets Z days), the following groups of apple polyphenol test tablets
- Group B 4 placebo tablets (150 mg Zl tablets) each before dinner (4 tablets Z days), below placebo tablets
- the subjects were instructed not to change their daily eating habits, smoking and exercising, except for taking test tablets daily.
- the administration was conducted twice, starting with the intake and 12 weeks after the intake (end of the intake). In principle, the test should be performed within 4 days before and after the test. The test date should be at least 4 hours after fasting and 2 hours after fasting. ⁇ was carried out.
- Table 4 shows the results. As a result of two-way analysis of variance, changes in total fat area (TFA), visceral fat area (VFA), and subcutaneous fat area (SFA) in all subjects were 12 weeks after ingestion in the placebo tablet group in TFA Although there was an increasing trend (p ⁇ 0.1), no fluctuation tendency was observed in the group receiving the apple polyphenol test tablets.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006510479A JPWO2005082390A1 (ja) | 2004-03-02 | 2005-02-25 | 脂肪蓄積抑制剤 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004057570 | 2004-03-02 | ||
JP2004-057570 | 2004-03-02 | ||
JP2005-002035 | 2005-01-07 | ||
JP2005002035 | 2005-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005082390A1 true WO2005082390A1 (ja) | 2005-09-09 |
Family
ID=34914488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/003178 WO2005082390A1 (ja) | 2004-03-02 | 2005-02-25 | 脂肪蓄積抑制剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2005082390A1 (ja) |
WO (1) | WO2005082390A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007111242A1 (ja) * | 2006-03-24 | 2007-10-04 | Rohto Pharmaceutical Co., Ltd. | メタボリック症候群改善剤 |
WO2010089874A1 (ja) * | 2009-02-05 | 2010-08-12 | フジッコ株式会社 | PPAR-γ発現増強剤、アディポネクチン産生促進剤、UCP活性剤およびそれらを用いた医薬品・飲食品 |
JP5177676B2 (ja) * | 2006-08-11 | 2013-04-03 | クラシエフーズ株式会社 | 脂肪吸収抑制剤及びそれを用いた飲食品 |
JP6154056B1 (ja) * | 2016-03-31 | 2017-06-28 | グレーシャス株式会社 | リンゴポリフェノール及びオレアノール酸を含有する食品組成物 |
CN107551065A (zh) * | 2016-07-01 | 2018-01-09 | 捷通国际有限公司 | 用于体重控制的基于植物的组合物和使用方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08198767A (ja) * | 1995-01-23 | 1996-08-06 | Pola Chem Ind Inc | 過剰体脂肪蓄積剤及びそれを含有する組成物 |
JPH09291039A (ja) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | プロシアニジンを有効成分とする抗肥満剤 |
JPH10330278A (ja) * | 1997-05-27 | 1998-12-15 | Nikka Uisukii Kk | 果実ポリフェノールを有効成分とする生体内脂質代謝制御剤 |
JP2003034636A (ja) * | 2001-07-19 | 2003-02-07 | Kao Corp | 脂質代謝改善剤 |
JP2003252766A (ja) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | シアニジン3−グルコシドを有効成分とする抗肥満及び/又は抗糖尿病剤 |
JP2005013091A (ja) * | 2003-06-26 | 2005-01-20 | Nakajima Suisan Bio & Techno Kk | 食肉用養鶏飼料及びその添加剤 |
-
2005
- 2005-02-25 WO PCT/JP2005/003178 patent/WO2005082390A1/ja active Application Filing
- 2005-02-25 JP JP2006510479A patent/JPWO2005082390A1/ja not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08198767A (ja) * | 1995-01-23 | 1996-08-06 | Pola Chem Ind Inc | 過剰体脂肪蓄積剤及びそれを含有する組成物 |
JPH09291039A (ja) * | 1995-12-26 | 1997-11-11 | Suntory Ltd | プロシアニジンを有効成分とする抗肥満剤 |
JPH10330278A (ja) * | 1997-05-27 | 1998-12-15 | Nikka Uisukii Kk | 果実ポリフェノールを有効成分とする生体内脂質代謝制御剤 |
JP2003034636A (ja) * | 2001-07-19 | 2003-02-07 | Kao Corp | 脂質代謝改善剤 |
JP2003252766A (ja) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | シアニジン3−グルコシドを有効成分とする抗肥満及び/又は抗糖尿病剤 |
JP2005013091A (ja) * | 2003-06-26 | 2005-01-20 | Nakajima Suisan Bio & Techno Kk | 食肉用養鶏飼料及びその添加剤 |
Non-Patent Citations (3)
Title |
---|
KAMEYAMA M. ET AL: "Catechin Oligomer wa Nanryotai made Aruka? Procyanidine no Chogo Dosu to Kassei Josho no Sokan Kankei.", KAGAKU DOSU SEIBUTSU., vol. 36, no. 12, 1998, pages 766 - 767, XP002996543 * |
NAGATA K. ET AL: "Ringo Mijuku Kaitsu Yurai Procyanidine-Rui no Shishitsu Taisha Chosetsu Kino to Kosanka Kino.", NEW FOOD INDUSTRY., vol. 45, no. 3, 2003, pages 1 - 6, XP002996542 * |
SHOJI T. ET AL: "Inhibitory Effects of Apple Polyphenols on Differentiation of 3T3-L1 Cells into Adipocytes.", FOOD SCI.TECHNOL.RES., vol. 6, no. 2, 2000, pages 119 - 121, XP002996541 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007111242A1 (ja) * | 2006-03-24 | 2007-10-04 | Rohto Pharmaceutical Co., Ltd. | メタボリック症候群改善剤 |
JP5177676B2 (ja) * | 2006-08-11 | 2013-04-03 | クラシエフーズ株式会社 | 脂肪吸収抑制剤及びそれを用いた飲食品 |
WO2010089874A1 (ja) * | 2009-02-05 | 2010-08-12 | フジッコ株式会社 | PPAR-γ発現増強剤、アディポネクチン産生促進剤、UCP活性剤およびそれらを用いた医薬品・飲食品 |
JP6154056B1 (ja) * | 2016-03-31 | 2017-06-28 | グレーシャス株式会社 | リンゴポリフェノール及びオレアノール酸を含有する食品組成物 |
CN107551065A (zh) * | 2016-07-01 | 2018-01-09 | 捷通国际有限公司 | 用于体重控制的基于植物的组合物和使用方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005082390A1 (ja) | 2007-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1312374B1 (en) | Primrose seed extracts as sugar absorption inhibitors and process for producing the same | |
Ahmadi et al. | Polyphenols and atherosclerosis: A critical review of clinical effects on LDL oxidation | |
KR101412221B1 (ko) | 구기자잎 추출 분말과 베타인을 유효성분으로 함유하는 항비만 조성물 | |
JP5121308B2 (ja) | メタボリックシンドロームの予防、改善または治療組成物 | |
KR20180043251A (ko) | 산화질소 수준을 급성으로 올리기 위한 조성물 및 방법 | |
US20080044453A1 (en) | Therapeutic Agent for Treatment of Autoimmune Diseases | |
TWI383753B (zh) | 用於增強運動能力的組合物 | |
WO2013078658A1 (en) | Morus berries and avoiding glucose peaks | |
RU2557408C2 (ru) | Комплекс неочищенного кофеина, улучшенные продукты питания с использованием комплекса неочищенного кофеина и способы их применения | |
JP2006193502A (ja) | アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬 | |
WO2005082390A1 (ja) | 脂肪蓄積抑制剤 | |
JP2009298769A (ja) | 脂肪蓄積抑制用組成物 | |
WO2006135084A1 (ja) | 脂肪性肝炎または脂肪肝の予防または治療薬 | |
EP1729598B1 (en) | Composition; use of a composition and a method for preventing fat absorption | |
US20220062312A1 (en) | Oral composition comprising b-escin and the use thereof | |
JP6105186B2 (ja) | 膵リパーゼ阻害剤 | |
WO2006064761A1 (ja) | アディポネクチン調節剤、それを含有する飲食品、食品添加物及び医薬 | |
US6599522B2 (en) | Triglyceride reducing agent | |
EP3235510A1 (en) | Nutritional compositions for the management of glucose metabolism | |
KR20130075442A (ko) | 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물 | |
JP2019180399A (ja) | 食後の血糖値上昇抑制用組成物 | |
JP2006089457A (ja) | コレステロール代謝制御剤、それを含有する飲食品、食品添加物及び医薬 | |
KR20200045036A (ko) | 식물 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물 | |
JP2012162472A (ja) | 脂質***促進剤 | |
KR20110100882A (ko) | 퀘르세틴을 유효성분으로 함유하는 지질대사 질환의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006510479 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |